Common Contracts

4 similar Merger Agreement contracts by 20/20 Biolabs, Inc., Aerovate Therapeutics, Inc., Allovir, Inc., Longevity Health Holdings, Inc.

AGREEMENT AND PLAN OF MERGER by and among LONGEVITY HEALTH HOLDINGS, INC., LONGEVITY HEALTH BIOMARKERS, INC., 20/20 BIOLABS, INC.,
Merger Agreement • April 18th, 2025 • 20/20 Biolabs, Inc. • Services-testing laboratories • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of April 11, 2025, by and among Longevity Health Holdings, Inc., a Delaware corporation (“Parent”), Longevity Health Biomarkers, Inc., a Delaware corporation (“Merger Sub”), 20/20 Biolabs, Inc., a Delaware corporation (the “Company”), and Jonathan Cohen, as the Stockholder Representative (the “Stockholder Representative”).

AGREEMENT AND PLAN OF MERGER by and among LONGEVITY HEALTH HOLDINGS, INC., LONGEVITY HEALTH BIOMARKERS, INC., 20/20 BIOLABS, INC., and Jonathan Cohen, as the Stockholder Representative Dated as of APRIL 11, 2025
Merger Agreement • April 14th, 2025 • Longevity Health Holdings, Inc. • Soap, detergents, cleang preparations, perfumes, cosmetics • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of April 11, 2025, by and among Longevity Health Holdings, Inc., a Delaware corporation (“Parent”), Longevity Health Biomarkers, Inc., a Delaware corporation (“Merger Sub”), 20/20 Biolabs, Inc., a Delaware corporation (the “Company”), and Jonathan Cohen, as the Stockholder Representative (the “Stockholder Representative”).

AGREEMENT AND PLAN OF MERGER by and among ALLOVIR, INC., AURORA MERGER SUB, INC. and KALARIS THERAPEUTICS, INC. Dated as of November 7, 2024
Merger Agreement • November 8th, 2024 • Allovir, Inc. • Biological products, (no disgnostic substances) • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of November 7, 2024, by and among AlloVir, Inc., a Delaware corporation (“Parent”), Aurora Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Kalaris Therapeutics, Inc., a Delaware corporation (the “Company”).

AGREEMENT AND PLAN OF MERGER by and among AEROVATE THERAPEUTICS, INC., CARIBBEAN MERGER SUB I, INC. CARIBBEAN MERGER SUB II, LLC and JADE BIOSCIENCES, INC. Dated as of October 30, 2024
Merger Agreement • October 31st, 2024 • Aerovate Therapeutics, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of October 30, 2024, by and among Aerovate Therapeutics, Inc., a Delaware corporation (“Parent”), Caribbean Merger Sub I, Inc., a Delaware corporation (“First Merger Sub”) and wholly owned subsidiary of Parent, Caribbean Merger Sub II, LLC, a Delaware limited liability company (“Second Merger Sub” and, together with First Merger Sub, “Merger Subs”) and wholly owned subsidiary of Parent, and Jade Biosciences, Inc., a Delaware corporation (the “Company”).